



For Immunization Managers

RSV Vaxview

WEEKLY

RSV

VACCINATION DASHBOARD

Weekly Respiratory Syncytial Virus (RSV) Vaccination Dashboard

The Weekly RSV Vaccination Dashboard is designed to share weekly RSV vaccination data, including coverage estimates and intent for vaccination, using a variety of data sources including surveys, healthcare claims, electronic medical records, and immunization information systems (IIS) data. The Dashboard will be updated weekly as new data become available. Please [email](#) to share any feedback.

Data Summary

Adults 60+ Coverage (NIS)



Data and Charts for Adults 60+ Coverage >

Adults 60+ RSV Vaccination Coverage

RSV vaccination coverage estimates among [adults 60 years and older](#) are based on data from CDC’s National Immunization Survey-Adult COVID Module. Estimates of vaccination coverage are based on respondent self-report.

- As of February 3, 2024, an estimated 22.4% (95% Confidence Interval: 21.1%-23.6%) of adults 60 years and older reported having received an RSV vaccine.

- An additional 13.3% (11.5%-15.1%) reported that they definitely plan to get vaccinated.
- White adults had higher vaccination coverage than adults in all other race and ethnicity groups, with coverage ranging from 9.3% (3.0%-15.7%) among Pacific Islander and Native Hawaiian adults to 25.1% (23.5%-26.7%) among non-Hispanic White adults.
- Vaccination coverage has also consistently varied by age, poverty status, health insurance status, urbanicity, gender identity, and chronic medical condition.
- Across states and the District of Columbia, receipt of an RSV vaccine was lowest in Mississippi [13.0% (9.8%-16.2%)] and highest in Washington [35.1% (24.7%-45.5%)].
- Additional RSV vaccination data by demographic characteristics at the national level and overall estimates by jurisdiction are [available](#).

Vaccine Administration and Coverage by Jurisdiction (IIS)

Data and Charts for Vaccine Administration and Coverage by Jurisdiction >

Vaccine Administration and Coverage by Jurisdiction

RSV vaccination coverage estimates as of the end of December 2023 based on IIS data submitted to CDC by 43 immunization awardee jurisdictions.

- Among the currently reporting 37 state and city IIS jurisdictions, RSV vaccination coverage among adults 60 years and older ranged from 4.6% to 17.9%. Among 6 reporting island jurisdictions, coverage ranged from 0.0% to 3.4%.

Adult Vaccinations Administered (IQVIA)

Data and Charts for Adult Vaccinations Administered >

RSV Vaccinations Administered in Pharmacies and Medical Offices (Data Source: IQVIA)

RSV vaccinations administered at pharmacies and physician medical offices for [adults 60 years and older](#) based on healthcare claims data.

- As of January 20, 2024, an estimated 9.02 million doses were administered in pharmacies and an estimated 274,189 doses were administered in physician medical offices to adults 60 years and older.

Pregnant Persons Coverage (VSD)

Data and Charts for Pregnant Persons Coverage >

Data for pregnant persons will be updated late in February due to data system updates at VSD sites.

Pregnant Persons RSV Vaccination Coverage

RSV vaccination coverage estimates for [pregnant persons](#) 18 to 49 years are based on data from CDC's [Vaccine Safety Datalink](#). Estimates of vaccination coverage are based on electronic health data from multiple integrated health systems.

- As of January 27, 2024, among persons who were pregnant and ≥ 32 weeks gestation since September 22, 2023, overall coverage with the RSV vaccine was 16.2%.
- Vaccination coverage was highest among non-Hispanic Asian (22.8%) pregnant persons and lowest among non-Hispanic Black (9.5%) pregnant persons.

Nirsevimab Coverage and Intent for Infants (NIS)

Data and Charts for Nirsevimab Coverage and Intent for Infants >

Monthly Nirsevimab Coverage and Intent for Infants

Monthly nirsevimab coverage and intent estimates reported by females aged 18-49 years with infants under the age of < 8 months, females aged 18-49 years who are currently pregnant, and females aged 18-49 years who are currently trying to get pregnant, are based on data from CDC’s National Immunization Survey-Adult COVID Module. Estimates of nirsevimab coverage and intent are based on respondent self-report.

- As of January 2024, among females with an infant <8 months, 40.5% reported that their infant received nirsevimab.
- An additional 21.7% reported that they definitely plan to get nirsevimab for their infant.
- Among females who were pregnant in January, 38.2% reported that they definitely plan to get nirsevimab for their infant, and among females who are trying to get pregnant, 44.4% reported that they definitely plan to get nirsevimab for their infant.

Nirsevimab Administration and Coverage by Jurisdiction (IIS)

Data and Charts for Jurisdiction Nirsevimab Administration and Coverage >

Monthly Jurisdiction Nirsevimab Administration and Coverage (IIS)

Nirsevimab administration and coverage estimates among infants aged <8 months as of the end of December 2023 based on IIS data submitted to CDC by 43 immunization awardee jurisdictions. These data do not include doses administered to infants born on or after October 1, 2023, and information on maternal vaccination status is not reported and not considered when calculating nirsevimab coverage.

- Among the currently reporting 37 state and city IIS jurisdictions, nirsevimab coverage among infants <8 months ranged from 1.6% to 20.5%. Among 6 reporting island jurisdictions, coverage ranged from 0.0% to 9.0%.

Data & Charts



Adults 60+ Coverage and Intent
(Data Source: NIS)



Vaccine Administration and Coverage by Jurisdiction
(Data Source: IIS)



Adult Vaccinations Administered

(Data Source: IQVIA)



Pregnant Persons Coverage

(Data Source: VSD)



Nirsevimab Coverage and Intent for Infants

(Data Source: NIS)



Nirsevimab Administration and Coverage by Jurisdiction

(Data Source: IIS)

Related Pages

Prevent RSV

[Adults 60 years and older](#) and [pregnant persons](#) can protect themselves from RSV.

Learn more about [RSV](#).